Table 2.

Observed and modeled percent of participants who lost at least 5% of baseline bodyweight at each 8-week time segment between the index GLP-1 agonist dispensing through week 72.

	Observed		Modeled
Time Window, weeks	n	(%)	%	(95% Confidence Interval)
8	118	(9.5)	11.2	(8.4, 14.1)
16	265	(17.6)	20.2	(16, 24.4)
24	315	(21.9)	24.7	(19.8, 29.7)
32	351	(24.8)	27.7	(22.2, 33.2)
40	365	(26.2)	29.8	(23.9, 35.6)
48	364	(26.6)	30.5	(24.6, 36.4)
56	378	(26.3)	30.7	(24.7, 36.7)
64	386	(29.1)	33.0	(26.6, 39.3)
72	391	(29.2)	33.3	(26.8, 39.7)

p-value for quadratic trend <0.001

Proportions and 95% confidence intervals were estimated using a Poisson mixed model with robust error variance with a person-level random intercept controlling for variables associated with missing follow-up weight (i.e., sex, smoking status, coronary artery disease, hypertension, coronary heart failure, chronic kidney disease, having at least one hospitalization, and HbA1c value)